GlaxoSmithKline will spend a record amount of money on legal fees associated with lawsuits against its controversial diabetes drug, Avandia, and other issues.
The British company, whose North American headquarters is in Research Triangle Park, said it expects to have $2.36 billion in legal payments and fees in the second quarter.